Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Feb;38(2):356–359. doi: 10.1128/aac.38.2.356

Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.

B E Gilbert 1, P R Wyde 1, G Lopez-Berestein 1, S Z Wilson 1
PMCID: PMC284455  PMID: 8192464

Abstract

Mice lethally infected with Candida albicans were exposed to small-particle aerosols containing amphotericin B-liposomes. The drug, when administered twice daily for 2 h (0.58 mg/kg of body weight per day) on days 1, 2, and 3 postinoculation, significantly reduced the numbers of Candida organisms in the kidneys. Aerosol treatment increased the survival time of mice given 2 2-h treatments once a week for 4 weeks. A twice-weekly, 2-h small-particle aerosol administration of amphotericin B-liposomes for 1, 2, or 3 weeks significantly increased both the mean time of survival and percent survival.

Full text

PDF
356

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark J. M., Whitney R. R., Olsen S. J., George R. J., Swerdel M. R., Kunselman L., Bonner D. P. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother. 1991 Apr;35(4):615–621. doi: 10.1128/aac.35.4.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Diamond R. D. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis. 1991 May-Jun;13(3):480–486. doi: 10.1093/clinids/13.3.480. [DOI] [PubMed] [Google Scholar]
  3. Garcon N. M., Six H. R., Frazer J., Hazlewood C., Gilbert B. E., Knight V. Liposomes of enviroxime and phosphatidylcholine: definition of the drug-phospholipid interactions. Antiviral Res. 1989 Mar;11(2):89–98. doi: 10.1016/0166-3542(89)90011-9. [DOI] [PubMed] [Google Scholar]
  4. Gilbert B. E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986 Aug;30(2):201–205. doi: 10.1128/aac.30.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gilbert B. E., Six H. R., Wilson S. Z., Wyde P. R., Knight V. Small particle aerosols of enviroxime-containing liposomes. Antiviral Res. 1988 Sep;9(6):355–365. doi: 10.1016/0166-3542(88)90037-x. [DOI] [PubMed] [Google Scholar]
  6. Gilbert B. E., Wyde P. R., Wilson S. Z. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother. 1992 Jul;36(7):1466–1471. doi: 10.1128/aac.36.7.1466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548. doi: 10.1128/aac.33.9.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hospenthal D. R., Rogers A. L., Beneke E. S. Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother. 1989 Jan;33(1):16–18. doi: 10.1128/aac.33.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Knight V., Gilbert B. Antiviral therapy with small particle aerosols. Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):721–731. doi: 10.1007/BF01975037. [DOI] [PubMed] [Google Scholar]
  10. Knight V., Yu C. P., Gilbert B. E., Divine G. W. Estimating the dosage of ribavirin aerosol according to age and other variables. J Infect Dis. 1988 Aug;158(2):443–448. doi: 10.1093/infdis/158.2.443. [DOI] [PubMed] [Google Scholar]
  11. Korting H. C., Ollert M., Georgii A., Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol. 1988 Dec;26(12):2626–2631. doi: 10.1128/jcm.26.12.2626-2631.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  13. Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. doi: 10.1093/infdis/147.5.939. [DOI] [PubMed] [Google Scholar]
  14. Niki Y., Bernard E. M., Schmitt H. J., Tong W. P., Edwards F. F., Armstrong D. Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother. 1990 Jan;34(1):29–32. doi: 10.1128/aac.34.1.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schmitt H. J., Bernard E. M., Häuser M., Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1988 Nov;32(11):1676–1679. doi: 10.1128/aac.32.11.1676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wyde P. R., Wilson S. Z., Gilbert B. E., Smith R. H. Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol. Antimicrob Agents Chemother. 1986 Dec;30(6):942–944. doi: 10.1128/aac.30.6.942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. van Etten E. W., van de Rhee N. E., van Kampen K. M., Bakker-Woudenberg I. A. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother. 1991 Nov;35(11):2275–2281. doi: 10.1128/aac.35.11.2275. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES